Clinical Trial Update: A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS) [Phase 3]

View source ↗

Summary

A Phase III randomized trial (ORCHID-PLUS) is evaluating oral chemotherapy plus trastuzumab versus paclitaxel plus trastuzumab as adjuvant therapy for HER2-posi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Oral chemotherapy (undisclosed)
• PACLITAXEL (PACLITAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Fudan University | Conditions: HER2-positive Breast Cancer | Phase 3 | Status: RECRUITING